Developer docs
API playgroundTry for free, no card

Search company profiles

Wellma

Full company profile

uuid000a94l

Namestring
Wellma
Legal namestring
Wellma Group AB
Websiteurl
wellma.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Wellma is a European contract development and manufacturing organization (CDMO) serving B2C nutraceutical brands and pharmaceutical companies. Founded in 2021 and headquartered in Stockholm (registered as Wellma Group AB), the company operates a federation of 15+ specialized development and manufacturing sites across Sweden, the UK, the Netherlands, Italy, Spain, Germany, and Denmark, each retained under its acquired brand and led by its founding managing director. The platform covers the full nutraceutical format spectrum — tablets, capsules, powders, gels, liquids, gummies, bars, softgels, coating and granulation, and liposomal technology — and is unified by GFSI-aligned certifications (FSSC 22000, IFS Food, BRCGS, cGMP) plus FDA, GACC, and ISO 56001 certifications.

The company makes money by selling formulation, development, production, packaging, and regulatory-support services to nutraceutical and pharmaceutical brand owners, with quote-based pricing and unit MOQs ranging from 80 kg (coating) to 300 kg (gummies) to 100,000 tablets. Service breadth spans R&D (e.g., NutraResearch), specialty actives (PlantaCorp's liposomal encapsulation), and high-volume manufacturing (e.g., Euronovis coating ~800 million tablets per year). Go-to-market is sales-led and direct, supported by LinkedIn presence, content marketing, and participation in industry trade shows such as Vitafoods Europe.

Reported sales scaled from over €50M (Feb 2024) to €120M+ (Apr 2025), a trajectory driven primarily by 8 acquisitions completed between August 2023 and October 2025. Subsidiaries include Legosan, Euronovis, Pouch Alliance, Calleva, MixMasters, NutraResearch, Nutrifundiet, Private Label Factory, PlantaCorp, The Bar Factory, and Fipros A/S, serving a long-tail of 150+ global brand customers across the nutraceutical and pharmaceutical sectors.

Short descriptiontext

Wellma is a European contract development and manufacturing organization (CDMO) that develops, formulates, and produces nutraceuticals and niche pharmaceuticals across all major formats for B2C brand owners. It operates a 15-site federation across seven European countries unified by GFSI-aligned certifications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract development manufacturing, nutraceutical CDMO services, pharmaceutical manufacturing, food supplement production, private label manufacturing
Industry2 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Development and Manufacturing (CDMO) for Nutraceuticals and Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Wellma generates revenue through providing development and manufacturing services to B2C brands in the nutraceutical and pharmaceutical space. Services span from formulation to production, packaging, and regulatory support across all product formats. The company operates through an ecosystem of specialized manufacturing sites across Europe.

wellma.com
2CDMO Services Revenue
TypeManaged Services
Description

Revenue from contract manufacturing organization services, with the company reporting €70M+ in sales (2023) growing to €100M+ (2024) and €120M+ (2025), indicating consistent growth in manufacturing service revenue.

wellma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Wellma is a European Contract Development and Manufacturing Organization (CDMO) platform serving the nutraceutical and pharmaceutical industries. The company provides end-to-end services spanning R&D, formulation, production, packaging, and regulatory support across all major product formats (tablets, capsules, powders, gels, liquids, gummies, bars, softgels, coating, granulation, pellets), delivered through an ecosystem of 15+ specialized manufacturing sites across Europe that each retain entrepreneurial leadership and deep format-specific expertise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Revenue growth from €70M+ (2023) to €120M+ (2025)
+3 more records
Product overview1 text field

Wellma is a European development and manufacturing partner (CDMO) for nutraceuticals and pharmaceuticals. The company operates a platform model combining specialized manufacturing sites across Europe under unified quality standards. The product portfolio includes core format capabilities: Tablets, Capsules, Powder, Gels, Liquids, Gummies, Bars, Softgels, Coating/Granulation/Pellets, and Special Liposomal Technology. Wellma has acquired/partnered with specialized companies including Legosan (Sweden - tablets/capsules), Calleva (UK - nutraceutical ingredients/gels), MixMasters (Netherlands - powders), Euronovis (Italy - coating/granulation), NutraResearch (Spain - R&D/liquids/solids), Nutrifundiet (Spain - gummies), Pouch Alliance (Netherlands - liquids/gels), Private Label Factory (Germany - digital manufacturing), PlantaCorp (Germany - liposomal technology), Fipros A/S (Denmark - gels/powders), and The Bar Factory (Netherlands - bars). Services span full product lifecycle from R&D, formulation, production, packaging, and regulatory support. The ecosystem enables cross-site collaboration to serve global customers with comprehensive format capabilities.

Product and service10 records
1Tablet Manufacturing
CategoryContract Manufacturing - Solid Dose
Description

Contract manufacturing of tablets for both nutraceuticals and pharmaceuticals, with wide diversity in shape and dissolution characteristics. Applications include multivitamins, probiotics, weight management, and herbal supplements. Packaging options include bottling, blistering, labeling with eco-friendly options. MOQ: 100k tablets.

2Capsule Manufacturing
CategoryContract Manufacturing - Solid Dose
Description

Contract manufacturing of capsules including vegan HPMC, gelatin, and acid-resistant variants in all sizes and applications. Designed for aesthetics, ease of swallowing, and taste-masking capabilities. MOQ: 500 bottles.

3Powder Manufacturing
CategoryContract Manufacturing - Powder Formats
Description

Contract manufacturing of unique tailored or standard powder recipes with unmatched flavoring capabilities. Products include pre-workouts, energy boosters, meal shakes, plant-based proteins, whey protein, and amino acids. Packaging in sachets, jars, pouches, and bags from 10g to 20kg. MOQ: 250 kg.

4Gel Manufacturing
CategoryContract Manufacturing - Liquid/Semi-Liquid Formats
Description

Contract manufacturing of nutritional gels including energy gels, protein gels, isotonic gels, vitamin and mineral shots, syrups, and liquid supplements. On-the-go, fast-acting formats ideal for sports and active nutrition applications. Packaging in single-serve flexible packs, tubes, and spouted stand-up pouches.

5Liquid Manufacturing
CategoryContract Manufacturing - Liquid Formats
Description

Contract manufacturing of liquid food supplements and functional beverages with custom formulations and excellent taste profiles. Includes vials, sprays, and drops with highly bioavailable shots and syrups for complex formulations. Packaging in single-serve flexible packs, tubes, vials, and stand-up pouches.

6Gummy Manufacturing
CategoryContract Manufacturing - Gummy Formats
Description

Contract manufacturing of nutraceutical gummies with customizable shapes and wide formulation capabilities including jelly bars. Vegan, sugar-free, and allergen-free options available. Bottling and labeling including eco-friendly options. MOQ: 300 kg.

7Bar Manufacturing
CategoryContract Manufacturing - Bar Formats
Description

Contract manufacturing of functional protein and energy bars for on-the-go nutrition with tailored flavor and function from energy to protein applications.

8Softgel Manufacturing
CategoryContract Manufacturing - Softgel Formats
Description

Contract manufacturing of high-absorption softgel format for oils and fat-soluble actives. Available in vegan, fish, and beef gelatins in oval and oblong shapes.

9Coating, Granulation and Pellet Services
CategoryContract Manufacturing - Specialty Processing
Description

Advanced contract coating, granulation, and pellet production services that adjust release patterns, mask unpleasant tastes, and improve shelf-life. Specialized facility exclusively focused on coating, granulation, and pellets. MOQ: 80 kg.

10Liposomal Technology R&D and Manufacturing
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Fipros A/S
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

Fipros A/S, a Danish CDMO specialized in powders and gels, joined Wellma. Founded in 1992 and headquartered in Funen, Denmark, the company operates from two sites and serves more than 150 customers globally. The company brings advanced automation and robotics capabilities developed over three decades.

wellma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-27
Description

The Bar Factory, a Dutch CDMO specialized in development and production of high-quality functional protein and energy bars, joined Wellma. Based in Duiven, Netherlands, the company focuses on formulation and production of premium bars known for superior taste, texture, and nutritional profile. This partnership expands Wellma into the functional bars segment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-07
Description

PlantaCorp, a German CDMO and leading innovator in liposomal technology for liquid formulations, partnered with Wellma. Based in Hamburg, Germany, PlantaCorp is known for cutting-edge R&D and proprietary liposomal encapsulation technology that enhances bioavailability of active ingredients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-29
Description

NutraResearch, a Barcelona-based R&D center and CDMO supporting development and production of nutraceutical products in liquid (vials, sprays, drops) and solid (tablets, capsules, powder) forms, joined Wellma. Renowned for advanced R&D capabilities and groundbreaking technological platform for next-generation food supplements.

5Nutrifundiet
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-24
Description

Nutrifundiet, a niche-focused developer and manufacturer for nutraceutical gummies based in Ávila near Madrid, Spain, joined Wellma. IFS certified plant with exceptional formulation capabilities and dedication to high-quality gummy supplements including vegan, sugar-free, and allergen-free options.

wellma.com
Strategic tierMinorTypeOthersAnnounced on2024-08-28
Description

Westcotts, a business advisory firm, facilitated the merger between Calleva and Wellma, representing Wellma's entry into the UK and European markets. The deal aligned interests of both parties and was structured to support future growth and expansion.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-09
Description

Calleva, a UK-based specialist in development and manufacturing of nutraceutical ingredients and products in nutritional gels, powder, and purpose-built ingredients, merged with Wellma. Based in Bridgwater, UK, Calleva brings capabilities in formulations, sourcing, excellent taste profiles, and BRC-certified manufacturing standards. This marked Wellma's entry into the UK market and first acquisition outside the EU.

8Pouch Alliance
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-07
Description

Pouch Alliance, a Dutch specialist in development and manufacturing of nutritional liquids and sport gels, joined Wellma. Based in Wormer, Netherlands, Pouch Alliance is a leader in formulating, producing, and packaging nutritional liquids including energy gels, vitamin/mineral shots, protein gels, isotonic gels, syrups, and liquid supplements with BRC Global Standard certification.

wellma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-12-15
Description

Private Label Factory (Germany) partnered with Legosan (Sweden) within the Wellma ecosystem to fulfill a large tablet order for a major retail client, demonstrating cross-site collaboration capabilities within Wellma's network.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-22
Description

Euronovis, an Italian coating and granulation specialist, became part of Wellma. Established in 2015 and based near Milan, Euronovis offers services for coating, granulation, pellet production, consultation, and formulation. Has capacity to coat over 800 million tablets per year and serves 40+ customers from 1,500 sqm cleanroom facility.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Swiss global CDMO leader across small molecules, biologics, and cell & gene therapy with a consumer health and nutrition segment. A scaled incumbent whose breadth dwarfs Wellma but who participates in the same end-markets.

2Martin Bauer Group
TypeDirect peer
Description

German family-owned supplier of botanical extracts, tea, and plant-based ingredients serving the nutraceutical and beverage industries. Comparable European specialist serving brand customers in supplements and functional beverages.

3Glatt Group
TypeDirect peer
Description

German family-owned group providing process technology, CDMO services, and integrated plant engineering for pharma, food, and nutraceutical applications including tablet coating and granulation — directly overlapping Euronovis's niche.

TypeDirect peer
Description

French-headquartered pan-European CDMO with manufacturing sites across France, Italy, Netherlands, and Canada, providing contract development and manufacturing for pharma and consumer health. Comparable multi-site, multi-country CDMO model.

TypeEmerging player
Description

Spanish life science company specializing in bioactive ingredients for nutraceutical and pharma applications, with CDMO-like manufacturing capabilities. Comparable European focus on nutraceutical ingredients and formulations.

TypeDirect peer
Description

German pharmaceutical manufacturer with significant consumer healthcare and OTC manufacturing capabilities, including effervescents and granulates. Comparable mid-sized European CDMO/CMO for brand customers.

7Recipharm
TypeDirect peer
Description

Swedish-headquartered European CDMO offering development and manufacturing services for pharmaceuticals and complex formulations across multiple dosage forms. Closest geographic and structural peer to Wellma, though Recipharm is much larger and more pharma-weighted.

TypeDirect peer
Description

Germany-based leading European CDMO for pharmaceuticals and nutraceuticals with broad format coverage including solids, semi-solids, liquids, and sterile products. Competes with Wellma for the same B2C brand customers across multiple formats.

TypeRegional player
Description

US-headquartered CDMO offering sterile fill-finish, oral solids, and analytical services. Comparable CDMO model but focused on the US market; relevant benchmark for CDMO service pricing and operations.

TypeBroad incumbent
Description

Global CDMO (now under Novo Holdings) with broad pharma and consumer health services including softgel, oral, and biologics capabilities. Much larger and broader than Wellma, but competes for the same mid-market brand customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wellma

Contract Development and Manufacturing (CDMO) for Nutraceuticals and Pharmaceuticalswellma.com

Wellma is a European contract development and manufacturing organization (CDMO) that develops, formulates, and produces nutraceuticals and niche pharmaceuticals across all major formats for B2C brand owners. It operates a 15-site federation across seven European countries unified by GFSI-aligned certifications.

What Wellma does

Wellma is a European contract development and manufacturing organization (CDMO) serving B2C nutraceutical brands and pharmaceutical companies. Founded in 2021 and headquartered in Stockholm (registered as Wellma Group AB), the company operates a federation of 15+ specialized development and manufacturing sites across Sweden, the UK, the Netherlands, Italy, Spain, Germany, and Denmark, each retained under its acquired brand and led by its founding managing director. The platform covers the full nutraceutical format spectrum — tablets, capsules, powders, gels, liquids, gummies, bars, softgels, coating and granulation, and liposomal technology — and is unified by GFSI-aligned certifications (FSSC 22000, IFS Food, BRCGS, cGMP) plus FDA, GACC, and ISO 56001 certifications.

The company makes money by selling formulation, development, production, packaging, and regulatory-support services to nutraceutical and pharmaceutical brand owners, with quote-based pricing and unit MOQs ranging from 80 kg (coating) to 300 kg (gummies) to 100,000 tablets. Service breadth spans R&D (e.g., NutraResearch), specialty actives (PlantaCorp's liposomal encapsulation), and high-volume manufacturing (e.g., Euronovis coating ~800 million tablets per year). Go-to-market is sales-led and direct, supported by LinkedIn presence, content marketing, and participation in industry trade shows such as Vitafoods Europe.

Reported sales scaled from over €50M (Feb 2024) to €120M+ (Apr 2025), a trajectory driven primarily by 8 acquisitions completed between August 2023 and October 2025. Subsidiaries include Legosan, Euronovis, Pouch Alliance, Calleva, MixMasters, NutraResearch, Nutrifundiet, Private Label Factory, PlantaCorp, The Bar Factory, and Fipros A/S, serving a long-tail of 150+ global brand customers across the nutraceutical and pharmaceutical sectors.

Wellma firmographics

Firmographics
Name
Wellma
Legal name
Wellma Group AB
Website
https://wellma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Short description
Wellma is a European contract development and manufacturing organization (CDMO) that develops, formulates, and produces nutraceuticals and niche pharmaceuticals across all major formats for B2C brand owners. It operates a 15-site federation across seven European countries unified by GFSI-aligned certifications.
Ownership category
akta.pro rank

Wellma industry classification

Industry
Product category
Contract Development and Manufacturing (CDMO) for Nutraceuticals and Pharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract development manufacturing
  • Nutraceutical CDMO services
  • Pharmaceutical manufacturing
  • Food supplement production
  • Private label manufacturing

Where Wellma is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Wellma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: Wellma generates revenue through providing development and manufacturing services to B2C brands in the nutraceutical and pharmaceutical space. Services span from formulation to production, packaging, and regulatory support across all product formats. The company operates through an ecosystem of specialized manufacturing sites across Europe.
  2. CDMO Services Revenue: Revenue from contract manufacturing organization services, with the company reporting €70M+ in sales (2023) growing to €100M+ (2024) and €120M+ (2025), indicating consistent growth in manufacturing service revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Wellma product offering

Product offering

Core offering

Wellma is a European Contract Development and Manufacturing Organization (CDMO) platform serving the nutraceutical and pharmaceutical industries. The company provides end-to-end services spanning R&D, formulation, production, packaging, and regulatory support across all major product formats (tablets, capsules, powders, gels, liquids, gummies, bars, softgels, coating, granulation, pellets), delivered through an ecosystem of 15+ specialized manufacturing sites across Europe that each retain entrepreneurial leadership and deep format-specific expertise.

Product overview

Wellma is a European development and manufacturing partner (CDMO) for nutraceuticals and pharmaceuticals. The company operates a platform model combining specialized manufacturing sites across Europe under unified quality standards. The product portfolio includes core format capabilities: Tablets, Capsules, Powder, Gels, Liquids, Gummies, Bars, Softgels, Coating/Granulation/Pellets, and Special Liposomal Technology. Wellma has acquired/partnered with specialized companies including Legosan (Sweden - tablets/capsules), Calleva (UK - nutraceutical ingredients/gels), MixMasters (Netherlands - powders), Euronovis (Italy - coating/granulation), NutraResearch (Spain - R&D/liquids/solids), Nutrifundiet (Spain - gummies), Pouch Alliance (Netherlands - liquids/gels), Private Label Factory (Germany - digital manufacturing), PlantaCorp (Germany - liposomal technology), Fipros A/S (Denmark - gels/powders), and The Bar Factory (Netherlands - bars). Services span full product lifecycle from R&D, formulation, production, packaging, and regulatory support. The ecosystem enables cross-site collaboration to serve global customers with comprehensive format capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tablet Manufacturing Contract manufacturing of tablets for both nutraceuticals and pharmaceuticals, with wide diversity in shape and dissolution characteristics. Applications include multivitamins, probiotics, weight management, and herbal supplements. Packaging options include bottling, blistering, labeling with eco-friendly options. MOQ: 100k tablets.
  • Capsule Manufacturing Contract manufacturing of capsules including vegan HPMC, gelatin, and acid-resistant variants in all sizes and applications. Designed for aesthetics, ease of swallowing, and taste-masking capabilities. MOQ: 500 bottles.
  • Powder Manufacturing Contract manufacturing of unique tailored or standard powder recipes with unmatched flavoring capabilities. Products include pre-workouts, energy boosters, meal shakes, plant-based proteins, whey protein, and amino acids. Packaging in sachets, jars, pouches, and bags from 10g to 20kg. MOQ: 250 kg.
  • Gel Manufacturing Contract manufacturing of nutritional gels including energy gels, protein gels, isotonic gels, vitamin and mineral shots, syrups, and liquid supplements. On-the-go, fast-acting formats ideal for sports and active nutrition applications. Packaging in single-serve flexible packs, tubes, and spouted stand-up pouches.
  • Liquid Manufacturing Contract manufacturing of liquid food supplements and functional beverages with custom formulations and excellent taste profiles. Includes vials, sprays, and drops with highly bioavailable shots and syrups for complex formulations. Packaging in single-serve flexible packs, tubes, vials, and stand-up pouches.
  • Gummy Manufacturing Contract manufacturing of nutraceutical gummies with customizable shapes and wide formulation capabilities including jelly bars. Vegan, sugar-free, and allergen-free options available. Bottling and labeling including eco-friendly options. MOQ: 300 kg.
  • Bar Manufacturing Contract manufacturing of functional protein and energy bars for on-the-go nutrition with tailored flavor and function from energy to protein applications.
  • Softgel Manufacturing Contract manufacturing of high-absorption softgel format for oils and fat-soluble actives. Available in vegan, fish, and beef gelatins in oval and oblong shapes.
  • Coating, Granulation and Pellet Services Advanced contract coating, granulation, and pellet production services that adjust release patterns, mask unpleasant tastes, and improve shelf-life. Specialized facility exclusively focused on coating, granulation, and pellets. MOQ: 80 kg.
  • Liposomal Technology R&D and Manufacturing

Quantifiable outcome

  • Revenue growth from €70M+ (2023) to €120M+ (2025)
  • +3 more outcomes

Companies that use Wellma

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Wellma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Wellma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Fipros A/ScoreStrategic or Co-development Partner · 8 October 2025Fipros A/S, a Danish CDMO specialized in powders and gels, joined Wellma. Founded in 1992 and headquartered in Funen, Denmark, the company operates from two sites and serves more than 150 customers globally. The company brings advanced automation and robotics capabilities developed over three decades.
  • The Bar FactorycoreStrategic or Co-development Partner · 27 June 2025The Bar Factory, a Dutch CDMO specialized in development and production of high-quality functional protein and energy bars, joined Wellma. Based in Duiven, Netherlands, the company focuses on formulation and production of premium bars known for superior taste, texture, and nutritional profile. This partnership expands Wellma into the functional bars segment.
  • PlantaCorpcoreStrategic or Co-development Partner · 7 April 2025PlantaCorp, a German CDMO and leading innovator in liposomal technology for liquid formulations, partnered with Wellma. Based in Hamburg, Germany, PlantaCorp is known for cutting-edge R&D and proprietary liposomal encapsulation technology that enhances bioavailability of active ingredients.
  • NutraResearchcoreStrategic or Co-development Partner · 29 January 2025NutraResearch, a Barcelona-based R&D center and CDMO supporting development and production of nutraceutical products in liquid (vials, sprays, drops) and solid (tablets, capsules, powder) forms, joined Wellma. Renowned for advanced R&D capabilities and groundbreaking technological platform for next-generation food supplements.
  • NutrifundietcoreStrategic or Co-development Partner · 24 January 2025Nutrifundiet, a niche-focused developer and manufacturer for nutraceutical gummies based in Ávila near Madrid, Spain, joined Wellma. IFS certified plant with exceptional formulation capabilities and dedication to high-quality gummy supplements including vegan, sugar-free, and allergen-free options.
  • WestcottsminorOthers · 28 August 2024Westcotts, a business advisory firm, facilitated the merger between Calleva and Wellma, representing Wellma's entry into the UK and European markets. The deal aligned interests of both parties and was structured to support future growth and expansion.
  • CallevacoreStrategic or Co-development Partner · 9 August 2024Calleva, a UK-based specialist in development and manufacturing of nutraceutical ingredients and products in nutritional gels, powder, and purpose-built ingredients, merged with Wellma. Based in Bridgwater, UK, Calleva brings capabilities in formulations, sourcing, excellent taste profiles, and BRC-certified manufacturing standards. This marked Wellma's entry into the UK market and first acquisition outside the EU.
  • Pouch AlliancecoreStrategic or Co-development Partner · 7 February 2024Pouch Alliance, a Dutch specialist in development and manufacturing of nutritional liquids and sport gels, joined Wellma. Based in Wormer, Netherlands, Pouch Alliance is a leader in formulating, producing, and packaging nutritional liquids including energy gels, vitamin/mineral shots, protein gels, isotonic gels, syrups, and liquid supplements with BRC Global Standard certification.
  • PLF-Legosan CollaborationminorStrategic or Co-development Partner · 15 December 2023Private Label Factory (Germany) partnered with Legosan (Sweden) within the Wellma ecosystem to fulfill a large tablet order for a major retail client, demonstrating cross-site collaboration capabilities within Wellma's network.
  • EuronoviscoreStrategic or Co-development Partner · 22 August 2023Euronovis, an Italian coating and granulation specialist, became part of Wellma. Established in 2015 and based near Milan, Euronovis offers services for coating, granulation, pellet production, consultation, and formulation. Has capacity to coat over 800 million tablets per year and serves 40+ customers from 1,500 sqm cleanroom facility.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Wellma competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Swiss global CDMO leader across small molecules, biologics, and cell & gene therapy with a consumer health and nutrition segment. A scaled incumbent whose breadth dwarfs Wellma but who participates in the same end-markets.
  • Catalent: Global CDMO (now under Novo Holdings) with broad pharma and consumer health services including softgel, oral, and biologics capabilities. Much larger and broader than Wellma, but competes for the same mid-market brand customers.

Direct peers

  • Martin Bauer Group: German family-owned supplier of botanical extracts, tea, and plant-based ingredients serving the nutraceutical and beverage industries. Comparable European specialist serving brand customers in supplements and functional beverages.
  • Glatt Group: German family-owned group providing process technology, CDMO services, and integrated plant engineering for pharma, food, and nutraceutical applications including tablet coating and granulation — directly overlapping Euronovis's niche.
  • Delpharm: French-headquartered pan-European CDMO with manufacturing sites across France, Italy, Netherlands, and Canada, providing contract development and manufacturing for pharma and consumer health. Comparable multi-site, multi-country CDMO model.
  • Hermes Arzneimittel: German pharmaceutical manufacturer with significant consumer healthcare and OTC manufacturing capabilities, including effervescents and granulates. Comparable mid-sized European CDMO/CMO for brand customers.
  • Recipharm: Swedish-headquartered European CDMO offering development and manufacturing services for pharmaceuticals and complex formulations across multiple dosage forms. Closest geographic and structural peer to Wellma, though Recipharm is much larger and more pharma-weighted.
  • Aenova: Germany-based leading European CDMO for pharmaceuticals and nutraceuticals with broad format coverage including solids, semi-solids, liquids, and sterile products. Competes with Wellma for the same B2C brand customers across multiple formats.

Emerging players

  • BIOIBERICA: Spanish life science company specializing in bioactive ingredients for nutraceutical and pharma applications, with CDMO-like manufacturing capabilities. Comparable European focus on nutraceutical ingredients and formulations.

Regional players

  • Alcami Corporation: US-headquartered CDMO offering sterile fill-finish, oral solids, and analytical services. Comparable CDMO model but focused on the US market; relevant benchmark for CDMO service pricing and operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Wellma social profiles

Digital presence

Wellma compliance and trust

Trust signal

Compliance9 records

Wellma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wellma leadership team

Management profile

Number of profiles

Profiles14 records

Wellma subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Wellma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wellma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellma

What does Wellma do?

Wellma is a European Contract Development and Manufacturing Organization (CDMO) platform serving the nutraceutical and pharmaceutical industries. The company provides end-to-end services spanning R&D, formulation, production, packaging, and regulatory support across all major product formats (tablets, capsules, powders, gels, liquids, gummies, bars, softgels, coating, granulation, pellets), delivered through an ecosystem of 15+ specialized manufacturing sites across Europe that each retain entrepreneurial leadership and deep format-specific expertise.

Is Wellma a public or private company?

Wellma is a private company. It is classified as unknown and is currently operating.

When was Wellma founded?

Wellma was founded in 2021. It employs 101 to 250 people.

Where is Wellma based?

Wellma is headquartered in Stockholm, Sweden, in the Europe region.

How does Wellma make money?

Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are CDMO Services Revenue.

Who are Wellma's main competitors?

Broad incumbents on record are Lonza and Catalent. Direct peers are Martin Bauer Group, Glatt Group, Delpharm, Hermes Arzneimittel, Recipharm and Aenova. BIOIBERICA is listed as an emerging player. Alcami Corporation is listed as a regional player.

Does Wellma have an API?

No public API is recorded for Wellma.

What industry is Wellma in?

Wellma's product category is Contract Development and Manufacturing (CDMO) for Nutraceuticals and Pharmaceuticals. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AffarsvarldenUppgifter: Svenska Wellma kan säljas för 1 miljard euroSystematic Growth plans to sell Swedish supplement maker Wellma for over 1 billion euros, with a sale process expected to start in October. The deal is in early stages, and Systematic Growth may choose to keep the company.Dagens industriUppgifter: Svensk entreprenör vill sälja bolag för 11 miljarderAshkan Pouya, a Swedish entrepreneur, plans to sell Wellma Group, a dietary supplement manufacturer, for about 11 billion kronor through his investment firm Systematic Growth. The deal was reported by Bloomberg citing sources.BloombergSwedish Food Supplement Firm Wellma Said to Seek €1 Billion Sale - BloombergSystematic Growth, owner of health supplements maker Wellma Group AB, is planning a sale of the Stockholm-based company, with a sales process expected to launch in October. The potential divestment could value Wellma at more than €1 billion ($1.1 billion).BridgwatermercuryNorth Petherton firm Calleva completes merger with WellmaCalleva Limited has merged with pharmaceuticals and nutraceuticals group Wellma, with the merger taking place in North Petherton. This acquisition marks Wellma's entry into the UK market, expanding its presence across Europe and enhancing its product development capabilities. The merger aligns Wellma's aims of innovation and quality with Calleva's expertise in nutraceutical ingredients.The Business MagazineCalleva merges with WellmaUK-based nutraceutical developer Calleva has merged with Swedish group Wellma in a multimillion-pound transaction. This acquisition marks Wellma's entry into the United Kingdom while allowing Calleva to expand its capabilities within Wellma's broader European presence.Business LiveBridgwater nutraceutical manufacturer merges with Swedish firmCalleva, a nutraceutical manufacturer based in Bridgwater, has merged with Swedish pharma group Wellma in a multimillion-pound deal. The acquisition marks Wellma's entry into the UK market and provides Calleva with access to expanded product portfolios and R&D capabilities.WellmaUK CDMO specialist Calleva joins WellmaWellma has acquired Calleva, a UK-based nutraceutical manufacturer, marking the company's entry into the United Kingdom market. This strategic move allows Wellma to expand its European presence beyond the EU while granting Calleva access to Wellma’s broader product portfolio and R&D capabilities.Calleva-NutritionCalleva joins forces with European group, Wellma.Calleva has joined forces with Wellma, a leading European nutraceutical and pharmaceutical development partner, to expand its strategic capabilities. This partnership grants Calleva access to Wellma’s wider product portfolio and R&D resources while marking Wellma's entry into the UK market.